BBOT Stock Analysis: Buy, Sell, or Hold?
BBOT - BridgeBio Oncology Therapeutics, Inc. Common Stock
$3.89
-0.05 (-1.27%)
▼
5d:
-1.52%
30d:
-56.24%
90d:
-53.75%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When BBOT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: BBOT shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: BBOT shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: BBOT is currently trading at $3.89, which is considered oversold relative to its 30-day fair value range of $4.14 to $8.55.
Technical Outlook: Technically, BBOT is in a downtrend. The price is currently testing key support at $3.79. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BBOT scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $24.55 (+531.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BBOT is in a downtrend. The price is currently testing key support at $3.79. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BBOT scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $24.55 (+531.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.14 -
$8.55
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 531.0% below Wall St target ($24.55)
- WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.14 -
$8.55
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.79
Resistance Level
$4.84
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.43
Wall Street Target
$24.55
(+531.0%)
Share & Embed Analysis
Last updated: October 03, 2026 1:12 AM ET
Data refreshes hourly during market hours. Next update: 2:12 AM
Data refreshes hourly during market hours. Next update: 2:12 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BBOT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 54 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 49 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$851 | 48 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$293 | 67 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 49 HOLD |
